Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Nemysis Limited |
| Country | Ireland |
| Start Date | Jun 01, 2023 |
| End Date | May 31, 2025 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190138713 |
E40 is a novel gluten degrading enzyme aimed at enhancing the degradation of ingested gluten, particularly in gluten intolerant Celiac Disease (CeD) and Non-Celiac Gluten Sensitivity (NCGS) sufferers.Different from any other competing enzymes under development, E40 efficiently exerts its gluten degrading activity in both the stomach and the intestine of CeD and NCGS sufferers, supporting the benefits of a Gluten Free Diet (GFD).
The final goal is to prevent symptomatology due to the pro-inflammatory reaction triggered by gluten.E40 will allow sufferers to manage inadvertent gluten exposure and will improve sufferer's Quality of Life, in particular allowing them to normalise their work and social life, reducing anxiety and allowing them to enjoy many everyday activities, like eating in a restaurant, travelling and visiting their friends in their homes.E40 is produced by an engineered, patented acidic Streptomyces lividans TK24 strain, and directly purified in its mature, functional form.
E40 activity has already been confirmed using the validated human simulated digestion INFOGEST assay of real food digestion: E40 gluten degradation leads to a gluten-free status (residual gluten
Nemysis Limited
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant